Immune Checkpoint Inhibitor
Phase 2Small molecule
Immune Checkpoint Inhibitor is one of 242 small molecule programs targeting Toxicity. It is currently in Phase 2.
9
Indications
31
Total Trials
17
Active Trials
241
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Immune Checkpoint Inhibitor
IImmuneSensor Therapeutics Inc.
Phase 2
DATROWAY
Daiichi SankyoPreclinical
MS Contin
Merck & Co.Preclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Tricor
JJagotec
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Lipegfilgrastim
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer3 trials
Lung Cancer2 trials
Immune Checkpoint Inhibitors2 trials
Immune Checkpoint Inhibitor2 trials
19 more indications
Immunotherapy2 trials
Priming Immunotherapy in Advanced Disease With Radiation
Completed·—·Phase 2·NCT03313804·76 enrolled
Adenocarcinoma1 trial
Metastatic NSCLC1 trial
Advanced or Metastatic Solid Tumors1 trial
Immune-related Adverse Events1 trial
Lymphoma1 trial
Solid Tumor Malignancies1 trial
Advanced/Metastatic Solid Tumors1 trial
Graft Rejection1 trial
Clinical Trial1 trial
Breast Cancer1 trial
Toxicity1 trial
Colorectal Cancer1 trial
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Recruiting·—·Phase 2·NCT06154538·170 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Immune Checkpoint Inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmuneSensor Therapeutics Inc.